Question Bank › Reporting the counterparty's growth as its own

Reporting the counterparty's growth as its own

Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust

Calls Tested
495
Answered YES
10
Hit Rate
2%
rare by design

Aehr Test Systems (AEHR) — this company's answers

NO on the Q2 2017 call 2017-01-05 F
The model's full reasoning — Q2 2017 call → NO我们根据提供的财报电话会议记录,判断管理层是否通过叙述其交易对手(客户)自身的扩张来讲述公司业务走向。关键点:管理层是否大量描述特定客户自己的增长、扩张、采用等,并将公司未来活动归因于这些客户的轨迹,且公司已嵌入其中,且该轨迹处于早期且规模大。 在记录中,管理层多次提到: - FOX-XP系统用于光学设备,客户是“lead customer”,已购买工程配置系统,正在演示烧录,预计夏季需要产能,但时间略有推迟。 - 提到“initial lead customer”需要系统支持生产烧录,但时间从第一季度末推迟到夏季。 - 提到“we continue to engage with our initial lead customer”,并说“we are successfully demonstrating burn-in of their devices on the FOX-XP system in our factory today”。 - 还提到“we’ve received information from this customer that implies a slightly later ramp”,以及“capacity shipments needed in the upcoming summer of 2017”。 - 此外,提到“we are taking several steps to shorten our lead times and ensure we have the capacity to meet a range of capacity needs and forecasts”。 - 还提到“we continue to be very excited about the sensor and photonics markets”,但更多是市场层面。 管理层确实在描述一个特定客户(lead customer)的产能需求时间线,并说公司正在为此做准备。但注意:该客户的需求被推迟了,且管理层说“could change on short notice”。此外,管理层也提到其他机会,但主要焦点是这个客户。 问题在于:管理层是否将公司前景主要描述为跟随该客户的扩张?管理层说“we remain optimistic about the opportunity to address this customer’s needs that span across multiple programs and applications”,但同时也提到其他市场。然而,在电话会议中,管理层确实花了不少篇幅谈论这个客户的需求时间线,并说公司正在准备产能以应对。但该客户的需求被推迟,且尚未有订单?实际上,该客户已经购买了工程系统,但生产系统尚未订购?管理层说“we are currently building several systems in anticipation of the need for shorter lead times”,但并未明确说已收到订单。此外,管理层说“we expect to ship our initial FOX-XP test cell in the current fiscal third quarter”,但那是针对另一个应用(光学设备)?实际上,管理层说“This system is configured for testing 18 wafers in parallel...

← Back to the full AEHR analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management explain where the company's business is going by NARRATING WHAT ITS COUNTERPARTIES ARE THEMSELVES DOING AND SCALING — that is, does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company ALREADY SUPPLIES OR SERVES, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? Answer YES when management's own words convey, in whatever form fits the industry, ONE coherent posture in which all three of the following come through as a present-tense reality: (1) MANAGEMENT SPEAKS ABOUT ITS COUNTERPARTIES' BUSINESS AS THOUGH IT WERE PART OF ITS OWN. In explaining the company's outlook, management devotes real substance to describing what identifiable counterparties are up to — their own ramps, launches, rollouts, capacity additions, adoption curves, program phases, store or site build-outs, production schedules, market entries, or spending plans — and treats those trajectories as the driver of the company's coming activity. The counterparties may be named or described unmistakably ("our lead customer," "the large operator we supply," "the national program we participate in"), and may be one dominant party or a small set. What matters is the DIRECTION OF EXPLANATION: management is reporting on somebody else's growth as the reason for its own, and speaks about that other party's plans with the familiarity of an insider to them. (2) THE COMPANY IS ALREADY INSIDE THAT GROWTH, NOT BIDDING FOR IT. Management makes clear the company is already supplying, serving, embedded in, specified into, or contracted to those counterparties — real current activity flowing today (shipments, deliveries, work performed, product in use, volumes recognized) — so the demand question is settled and what remains is how far the counterparties' own trajectories carry the company. Interest, pipeline, prospects being courted, bids outstanding, or relationships still contingent on approvals or decisions do NOT satisfy this. (3) THE COUNTERPARTIES' TRAJECTORY IS EARLY AND LARGE RELATIVE TO THE COMPANY. Management conveys, directly or plainly in substance, that these parties are still in the early or intensifying part of what they are doing — more phases, sites, volumes, regions, or years ahead — and that what has reached the company so far is small relative to what their continued growth implies, so the results just reported reflect the company before that growth arrives. Management may express this by discussing how it is preparing capacity or staffing for volumes not yet arriving, by contrasting today's contribution against the counterparties' stated plans, or by describing which phase of the counterparties' build-out is now beginning. The essence is ONE phenomenon: a company whose forward story has become a report on somebody else's expansion, where the decision to use this company is already made, the money is already flowing, and the expansion is young. The industry, the counterparty type, and what the company provides may vary widely. Answer NO if management explains its outlook chiefly through its own actions — new products, selling effort, marketing, pricing, capacity additions, cost programs, share gains — or through broad market, industry, or macro conditions, without narrating identifiable counterparties' own trajectories. NO if the counterparties described are prospects, targets, or parties the company hopes to win rather than ones it already serves. NO if the counterparties' activity is described as flat, mature, decelerating, being digested, at risk, or being renegotiated downward. NO if the company's participation in that activity is already fully reflected in reported results, with no meaningful ramp ahead. NO if the counterparty relationship is discussed only as a concentration risk, a source of lumpiness, or a passing statistic without its trajectory governing the forward account. NO if the company is large or diversified enough that these counterparties' growth would not visibly change its trajectory. NO if management merely reports strong demand from customers generally, without describing what specific counterparties are themselves building or scaling. NO if the counterparties' plans appear only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
EMKR EMCORE Corporation Q4 2023 2023-12-12 C+
MBLY Mobileye Global Inc. Q2 2023 2023-07-28 B+
PI Impinj, Inc. Q4 2022 2023-02-08 B+
FAT FAT Brands Inc. Q4 2021 2022-03-21 F
OOMA Ooma, Inc. Q3 2022 2021-12-02 B+
ILMN Illumina, Inc. Q1 2018 2018-04-24 A
PLAB Photronics, Inc. Q2 2017 2017-05-17 C+
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
FNV Franco-Nevada Corporation Q3 2016 2016-11-08 B+
HXL Hexcel Corporation Q4 2015 2016-01-22 B+

How the model reasoned

OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.

More from the question bank

The feared thing keeps not happeningNew normal declared and staffedDoors opening at the company's own gatesDemand arrived first, the company is growingSecond proving already underwayRacing a clock somebody else setAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.